triphosphoric acid has been researched along with Myasthenia Gravis in 1 studies
triphosphoric acid: used as water softener, peptizing agent, emulsifier & dispersing agent; ingredient of cleansers; meat preservative; RN given refers to parent cpd; structure
Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| COIRAULT, R | 1 |
| LEVY, J | 1 |
| MICHEL-BER, E | 1 |
| MASBERNARD, A | 1 |
| DESCLOS, S | 1 |
| MAZINGANT, F | 1 |
1 other study available for triphosphoric acid and Myasthenia Gravis
| Article | Year |
|---|---|
[Uridine-5-triphosphoric acid in therapeutics. II. Treatment of myopathies, myotonia, myasthenia and fatigue states].
Topics: Fatigue; Humans; Muscle Weakness; Muscular Diseases; Myasthenia Gravis; Myotonia; Polyphosphates; Ur | 1960 |